- Pacific Biosciences of California's long-read instruments can be used by labs to identify the complete coronavirus genome, even after mutations.
- This ability is playing an important role in virus surveillance.
- Revenues have been consistently increasing during the last three quarters in contrast to its short-read competitor.
- Equipped with cash and more sales staff, revenues should increase by triple digits in the second half of the year, but this will also depend on the ability to scale up production.
- A target share price of $40-42 is forecasted for this stock, which also forms part of Cathie Wood's ARKG, but market fluctuations impacting tech stocks currently prevail.
For further details see:
Pacific Biosciences: An Essential Component Of COVID Surveillance